JP2022505597A5 - - Google Patents
Info
- Publication number
- JP2022505597A5 JP2022505597A5 JP2021521995A JP2021521995A JP2022505597A5 JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5 JP 2021521995 A JP2021521995 A JP 2021521995A JP 2021521995 A JP2021521995 A JP 2021521995A JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- salt according
- fluorine atoms
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862750395P | 2018-10-25 | 2018-10-25 | |
| US62/750,395 | 2018-10-25 | ||
| PCT/IB2019/059004 WO2020084480A1 (en) | 2018-10-25 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505597A JP2022505597A (ja) | 2022-01-14 |
| JP2022505597A5 true JP2022505597A5 (https=) | 2022-10-11 |
| JP7500555B2 JP7500555B2 (ja) | 2024-06-17 |
Family
ID=68344929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521995A Active JP7500555B2 (ja) | 2018-10-25 | 2019-10-22 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210393633A1 (https=) |
| EP (1) | EP3870575B1 (https=) |
| JP (1) | JP7500555B2 (https=) |
| ES (1) | ES2942998T3 (https=) |
| PT (1) | PT3870575T (https=) |
| WO (1) | WO2020084480A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| ES2971987T3 (es) * | 2018-10-24 | 2024-06-10 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| US11541055B2 (en) | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3873607B1 (en) * | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| US20220211704A1 (en) * | 2019-04-30 | 2022-07-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP2022548690A (ja) * | 2019-09-20 | 2022-11-21 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20220370451A1 (en) * | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| EP4066839A4 (en) | 2019-11-28 | 2023-12-27 | Shionogi & Co., Ltd | PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) * | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| JP2022506399A (ja) * | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
-
2019
- 2019-10-22 JP JP2021521995A patent/JP7500555B2/ja active Active
- 2019-10-22 WO PCT/IB2019/059004 patent/WO2020084480A1/en not_active Ceased
- 2019-10-22 EP EP19794679.1A patent/EP3870575B1/en active Active
- 2019-10-22 ES ES19794679T patent/ES2942998T3/es active Active
- 2019-10-22 PT PT197946791T patent/PT3870575T/pt unknown
- 2019-10-22 US US17/284,855 patent/US20210393633A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505597A5 (https=) | ||
| JP2022505841A5 (https=) | ||
| JP2022505989A5 (https=) | ||
| JP2022505637A5 (https=) | ||
| JP2022500425A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2022141835A5 (https=) | ||
| JP2016527217A5 (https=) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| JP2005523922A5 (https=) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016510038A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2006528700A5 (https=) | ||
| JP2019500387A5 (https=) | ||
| JP2025071130A5 (https=) | ||
| JP2020512337A5 (https=) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2022525013A5 (https=) | ||
| JP2017141277A5 (https=) | ||
| JP2004517843A5 (https=) | ||
| JP2019501879A5 (https=) | ||
| RU2010142847A (ru) | Противовоспалительные агенты | |
| JP2010505865A5 (https=) |